

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED**

### **紛美包裝有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00468)**

- (1) FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND DELAY IN PUBLICATION OF THE 2025 INTERIM RESULTS;**
- (2) PUBLICATION OF UNAUDITED MANAGEMENT ACCOUNTS FOR THE SIX MONTHS ENDED 30 JUNE 2025;**
- AND**
- (3) CONTINUED SUSPENSION OF TRADING**

### **INTRODUCTION**

This announcement is made by Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to: (i) the announcement of the Company dated 28 February 2025 in relation to, amongst others, the establishment of the special investigation committee (the “**28 February Announcement**”); (ii) the announcements of the Company dated 25 March 2025, 30 April 2025, 13 June 2025 and 31 July 2025 (the “**31 July Announcement**”) in relation to, amongst others, the delay in publication of the annual results announcement of the Company for the year ended 31 December 2024 (the “**2024 Annual Results**”); and (iii) the announcement of the Company dated 18 August 2025 in relation to, amongst others, the publication of the unaudited management accounts for the year ended 31 December 2024 (the “**2024 Management Accounts Announcement**”, together with the announcements under paragraph (i) and (ii), the “**Announcements**”). Unless otherwise defined herein, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

## **FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND DELAY IN PUBLICATION OF THE 2025 INTERIM RESULTS**

In the 31 July Announcement, it was disclosed that the Company expected that the 2024 Annual Results would be published before 28 August 2025.

The Board wishes to announce that, as the Investigation (as outlined in the 28 February Announcement) is in the process of being finalized, the Company expects that the audit procedures for the 2024 Annual Results would not be able to be completed before 28 August 2025. Accordingly, the Company expects that the 2024 Annual Results would not be published before 28 August 2025.

Due to the further delay in publication of the 2024 Annual Results, the Company expects that the interim results of the Group for the six months ended 30 June 2025 (the “**2025 Interim Results**”) would not be published on or before 31 August 2025, being the date on which the Company is required to publish the 2025 Interim Results under Rules 13.49(6).

The Company is working closely with Grant Thornton Advisory and the Auditors with a view to finalizing the outstanding work and completing the audit of the 2024 Annual Results as soon as practicable. As at the date of this announcement and taking into account the current situation, it is expected that the 2024 Annual Results will be published on or before 31 October 2025, subject to the completion of all audit work as agreed with the Auditors and all of the outstanding items as mentioned above having been resolved. Assuming the 2024 Annual Results is being published on or before 31 October 2025, it is expected that the 2025 Interim Results will be published on or before 28 November 2025.

## **PUBLICATION OF THE UNAUDITED MANAGEMENT ACCOUNTS FOR THE SIX MONTHS ENDED 30 JUNE 2025**

In light of the expected delay in publication of the 2025 Interim Results as set out above, in order to keep the Shareholders and potential investors of the Company informed of the Group’s business operations and financial position, the Company would like to provide the Shareholders and potential investors of the Company with preliminary unaudited financial information of the Group for the six months ended 30 June 2025 (prepared on the basis of the Deconsolidation), which was extracted from the management accounts of the Group for the six months ended 30 June 2025, together with the restated comparative figures for the six months ended 30 June 2024 for the consolidated statement of comprehensive income and as at 31 December 2024 for the consolidated statement of financial position.

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Six months ended 30 June

	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited) (restated)

### Continuing operations

Revenue	1,017,432	1,023,465
Cost of sales	<u>(851,832)</u>	<u>(839,700)</u>

### Gross profit

Other income	25,259	28,691
Other (losses)/gains – net	1,034	3,367
Impairment losses on financial assets	(3,903)	(6,192)
Fair value gains on financial assets at fair value through profit or loss (“FVTPL”)	9,261	2,383
Share of profit of associates	25,932	23,581
Distribution expenses	(32,707)	(29,412)
Administrative expenses	<u>(76,483)</u>	<u>(88,723)</u>

### Operating profit

Finance costs	(513)	(1,908)
---------------	-------	---------

### Profit before income tax

Income tax expense	(16,537)	(24,110)
--------------------	----------	----------

### Profit for the period from continuing operations

	<u>96,943</u>	<u>91,442</u>
--	---------------	---------------

### Discontinued operations

Profit for the period from discontinued operations	<u>–</u>	<u>31,344</u>
--	----------	---------------

### Profit for the period

	<u>96,943</u>	<u>122,786</u>
--	---------------	----------------

### Profit for the period attributable to equity owners of the Company:

– From continuing operations	96,943	91,442
– From discontinued operations	<u>–</u>	<u>31,344</u>

	<u>96,943</u>	<u>122,786</u>
--	---------------	----------------

<b>Six months ended 30 June</b>	
<b>2025</b>	<b>2024</b>
<b>RMB'000</b>	<b>RMB'000</b>
<b>(Unaudited)</b>	<b>(Unaudited)</b>
	<b>(restated)</b>

**Other comprehensive (expense)/income:**

Item that may be reclassified to profit or loss

Currency translation differences	<u>12,974</u>	<u>(9,489)</u>
----------------------------------	---------------	----------------

Share of other comprehensive expense of associates, net of related income tax

Exchange difference released upon disposal of subsidiaries

<b>Total comprehensive income for the period</b>	<b>109,917</b>	<b>113,297</b>
--	----------------	----------------

**Total comprehensive income attributable to:**

Owners of the Company	<b>109,917</b>	<b>113,297</b>
-----------------------	----------------	----------------

Non-controlling interests	<u>—</u>	<u>—</u>
---------------------------	----------	----------

	<u><b>109,917</b></u>	<u><b>113,297</b></u>
--	-----------------------	-----------------------

*Note 1:* The presentation of comparative information in respect of the consolidated statement of comprehensive income for the six months ended 30 June 2024 has been restated in order to disclose the discontinued operations separately from continuing operations.

As the Target Group represented a separate geographical area of operations and was part of a single co-ordinated plan to dispose of a separate geographical area of operation, in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operation, the disposal of the Target Group was classified as discontinued operations. The results of the Target Group for the period from 1 January 2024 to 25 January 2024 are presented as discontinued operations in the consolidated statement of comprehensive income for the six months ended 30 June 2024. The comparative figures in the consolidated statement of comprehensive income for the six months ended 30 June 2024 have been restated to reflect the reclassification between continuing operations and discontinued operation of the Group accordingly.

*Note 2:* In view of the changes in the composition of the Board and its key members during the six months ended 30 June 2025, the Group's ability to continue to exercise significant influence over the financial and operational activities of the Target Group has been affected. The Group will assess based on the prevailing circumstances at relevant time.

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at <b>30 June</b> <b>2025</b> <i>RMB'000</i> <b>(Unaudited)</b>	As at 31 December 2024 <i>RMB'000</i> (Unaudited)
<b>ASSETS</b>		
<b>Non-current assets</b>	<b>628,053</b>	670,765
Property, plant and equipment	<b>39,994</b>	43,914
Right-of-use assets	–	425,130
Interests in associates	<b>521,914</b>	–
Other equity instruments investments	<b>549,788</b>	541,041
Financial assets at FVTPL	<b>54,639</b>	54,153
Intangible assets	<b>36,522</b>	36,523
Deferred income tax assets	<b>196,432</b>	61,216
Trade receivables	<b>125</b>	1,189
Prepayments	<b>2,027,467</b>	1,833,931
	<hr/>	<hr/>
<b>Current assets</b>		
Inventories	<b>493,503</b>	586,842
Trade and notes receivables	<b>583,672</b>	570,316
Prepayments	<b>9,794</b>	18,366
Other receivables	<b>46,536</b>	7,889
Contract assets	<b>6,653</b>	–
Amount due from an associate	–	11,919
Restricted cash	<b>142,891</b>	135,236
Cash and cash equivalents	<b>568,594</b>	748,255
	<hr/>	<hr/>
	<b>1,851,643</b>	2,078,823
	<hr/>	<hr/>
<b>Total assets</b>	<b>3,879,110</b>	3,912,754

	As at 30 June 2025 <i>RMB'000</i> (Unaudited)	As at 31 December 2024 <i>RMB'000</i> (Unaudited)
<b>EQUITY</b>		
<b>Capital and reserves attributable to equity holders of the Company</b>		
Share capital, share premium and capital reserve	603,809	603,809
Statutory reserve	339,947	339,947
Exchange reserve	(61,920)	(74,894)
Other comprehensive income	57,877	–
Retained earnings	<u>2,351,106</u>	<u>2,254,163</u>
<b>Total equity</b>	<u><b>3,290,819</b></u>	<u>3,123,025</u>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Deferred government grants	6,481	7,295
Lease liabilities	813	4,412
Deferred income tax liabilities	<u>16,947</u>	<u>16,863</u>
	<u><b>24,241</b></u>	<u>28,570</u>
<b>Current liabilities</b>		
Deferred government grants	1,574	1,519
Contract liabilities	12,941	16,074
Trade payables, other payables and accruals	524,361	648,671
Income tax liabilities	24,259	17,465
Borrowings	–	76,462
Lease liabilities	<u>915</u>	<u>968</u>
	<u><b>564,050</b></u>	<u>761,159</u>
<b>Total liabilities</b>	<u><b>588,291</b></u>	<u>789,729</u>
<b>Total equity and liabilities</b>	<u><b>3,879,110</b></u>	<u>3,912,754</u>
<b>Net current assets</b>	<u><b>1,287,593</b></u>	<u>1,317,664</u>
<b>Total assets less current liabilities</b>	<u><b>3,315,060</b></u>	<u>3,151,595</u>

*Note 2:* In view of the changes in the composition of the Board and its key members during the six months ended 30 June 2025, the Group's ability to continue to exercise significant influence over the financial and operational activities of the Target Group has been affected. The Group will assess based on the prevailing circumstances at relevant time.

**The Board wishes to emphasise that the unaudited financial information set out above is subject to, among others, further review by the Company and any potential adjustments to the 2024 Annual Results that might be proposed by the Auditors (and any corresponding changes required to be made to the 2025 Interim Results) pending the completion of the Investigation, and has therefore not been reviewed by the Audit Committee, nor has it been reviewed, audited or approved by the Auditor. The unaudited financial information above is only based on the preliminary assessment by the Board on the unaudited management accounts of the Group for the six months ended 30 June 2025, and is not based on any data or information that has been audited, reviewed or approved by the Auditors, the Audit Committee and the Company. The unaudited financial information will be subject to changes resulting from, among others, further review by the Company and any adjustments that may be made by the Auditors subject to the completion of the Investigation and the auditing process. The Board cannot guarantee the unaudited financial information set out above truly reflects the financial performance and condition of the Group and such information might be misleading if any potential adjustments have not been taken into account. Shareholders and potential investors should note that the actual 2025 Interim Results may be different from the disclosure in this announcement.**

**Shareholders and potential investors should exercise extreme caution when considering the unaudited financial information disclosed above and when dealing in the shares of the Company.**

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules and the Resumption Guidance to keep its shareholders and potential investors informed of (i) the resumption progress; (ii) the publication of the 2024 Annual Results and the 2025 Interim Results; (iii) the despatch of the 2024 Annual Report; and (iv) the date

of the board meeting for the purposes of considering and approving, amongst others, the 2024 Annual Results and the 2025 Interim Results. The Company will also provide updates as and when appropriate on the despatch of the interim report of the Group for the six months ended 30 June 2025.

By order of the Board  
**Greatview Aseptic Packaging Company Limited**  
**WANG Ziting**  
*Chairman and Executive Director*

Beijing, the People's Republic of China, 22 August 2025

*As at the date of this announcement, the Board comprises three executive directors, namely, Ms. WANG Ziting, Mr. YUAN Xunjun and Mr. LEE Hsien Dar Victor; four non-executive directors, namely, Ms. WANG Yingli, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. LI Weijin; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi.*